About Shane Schaffer
Shane J. Schaffer is the Co-founder, Chairman, and Chief Executive Officer (CEO) at Cingulate Therapeutics, located in Kansas City, Kansas. Cingulate Therapeutics is a Phase 3 clinical-stage biopharmaceutical company that builds and manages several branded next-generation pharmaceutical products. With particular reference to Attention Deficit/Hyperactivity Disorders (ADHD), Cingulate spans other therapeutic areas, including anxiety disorders and insomnia.
Dr. Schaffer is a 25-year pharmaceutical industry expert specializing in drug development and commercialization. His thoughtful leadership and entrepreneurial spirit in various business operations, including product launches, brand planning, joint venture brand management, life cycle management, and market development, make him a recognized personality in the biopharmaceutical and marketing space.
Dr. Schaffer completed his doctoral degree in Pharmacy from the University of Kansas in 1999. Later, he attended Rutgers University’s College of Pharmacy for a post-doctoral pharmaceutical industry fellowship. During his fellowship, he worked for Pfizer Worldwide Marketing and Morris Plains.
Portfolio
Shane Schaffer
